3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Gynecologic
5
Sarcoma
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
13
Lymphoma
6
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Non-Hodgkin
4
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Leukemia, Myeloid, Acute
3
Waldenstrom Macroglobulinemia
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Sarcoma
1
Primary Myelofibrosis
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Prolymphocytic
1
Leukemia, Biphenotypic, Acute
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioma
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
3
copanlisib
2
aflibercept
2
X-Rays
2
Specimen Handling
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
temsirolimus
1
selinexor
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
epacadostat
1
enzalutamide
1
entinostat
1
defactinib
1
dabrafenib
1
ciforadenant
1
capivasertib
1
binimetinib
1
atezolizumab
1
adavosertib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
selinexor
×
Lymphoid
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available